SG11201805592RA - Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor - Google Patents

Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor

Info

Publication number
SG11201805592RA
SG11201805592RA SG11201805592RA SG11201805592RA SG11201805592RA SG 11201805592R A SG11201805592R A SG 11201805592RA SG 11201805592R A SG11201805592R A SG 11201805592RA SG 11201805592R A SG11201805592R A SG 11201805592RA SG 11201805592R A SG11201805592R A SG 11201805592RA
Authority
SG
Singapore
Prior art keywords
emeryville
suite
california
street
horton
Prior art date
Application number
SG11201805592RA
Inventor
Kevin T Chapman
Mark P White
Xiaohua Wang
Minha Park
Guido K Stadler
Lowe, Jr
Radstrom Xiao Guan
Jason M Mcewen
Gang Wang
George L Fox
Peggy A Radel
Original Assignee
Berkeley Lights Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berkeley Lights Inc filed Critical Berkeley Lights Inc
Publication of SG11201805592RA publication Critical patent/SG11201805592RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
    • B01L2200/0652—Sorting or classification of particles or molecules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0819—Microarrays; Biochips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111 0111011101110011110111 10111110H III International Bureau 0.. .... .. ..... ..or:;„, (10) International Publication Number (43) International Publication Date WO 2017/123978 Al 20 July 2017 (20.07.2017) WIPO I PCT (51) International Patent Classification: [CN/US]; 5858 Horton Street, Suite 320, Emeryville, Cali- C07K16/00 (2006.01) C07K 16/30 (2006.01) fornia 94608 (US). FOX, George L. [US/US]; 5858 Hor- C07K 16/28 (2006.01) G01N 33/569 (2006.01) ton Street, Suite 320, Emeryville, California 94608 (US). RADEL, Peggy A. [US/US]; 5858 Horton Street, Suite (21) International Application Number: 320, Emeryville, California 94608 (US). PCT/US2017/013483 (74) Agents: MCNEILL, Rebecca M. et al.; McNeill Baur (22) International Filing Date: PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, 13 January 2017 (13.01.2017) Massachusetts 02140 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 62/279,341 15 January 2016 (15.01.2016) US DO, DZ, EC, EE, EG, ES, FE GB, GD, GE, GH, GM, GT, 62/411,690 23 October 2016 (23.10.2016) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 62/412,092 24 October 2016 (24.10.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicant: BERKELEY LIGHTS, INC. [US/US]; 5858 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Horton Street, Suite 320, Emeryville, California 94608 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (US). RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (72) Inventors; and ZA, ZM, ZW. (71) Applicants : CHAPMAN, Kevin T. [US/US]; 5858 Hor- - ton Street, Suite 320, Emeryville, California 94608 (US). (84) Designated States (unless otherwise indicated, for every _ kind ARIPO (BW, GH, WHITE, Mark P. [US/US]; 5858 Horton Street, Suite of regional protection available): GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 320, Emeryville, California 94608 (US). WANG, Xiaohua = 5858 Horton Street, Suite 320, Emeryville, Cali- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [CN/US]; fornia 94608 (US). PARK, Minha [US/US]; 5858 Horton TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FE FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, = Street, Suite 320, Emeryville, California 94608 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, STADLER, Guido K. [AT/US]; 5858 Horton Street, Emeryville, California 94608 (US). LOWE, JR., Randall SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, = D. 5858 Horton Street, Suite 320, Emeryville, GW, KM, ML, MR, NE, SN, TD, TG). [US/US]; = California 94608 (US). GUAN, Xiao [CN/US]; 5858 Hor- Published: = ton Street, Suite 320, Emeryville, California 94608 (US). with international search report (Art. 21(3)) — MCEWEN, Jason M. [US/US]; 5858 Horton Street, Suite 320, Emeryville, California 94608 (US). WANG, Gang, F. = = = = = = = 1-1 GC IN C :N (54) Title: METHODS OF PRODUCING PATIENT-SPECIFIC ANTI-CANCER THERAPEUTICS AND METHODS OF TREAT- en el MENT THEREFOR 1-1 ---- (57) : A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from IN at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a C flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissoci - el ated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) us - , ing the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells ,71 . 9 can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engin - .,. eered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.
SG11201805592RA 2016-01-15 2017-01-13 Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor SG11201805592RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662279341P 2016-01-15 2016-01-15
US201662411690P 2016-10-23 2016-10-23
US201662412092P 2016-10-24 2016-10-24
PCT/US2017/013483 WO2017123978A1 (en) 2016-01-15 2017-01-13 Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor

Publications (1)

Publication Number Publication Date
SG11201805592RA true SG11201805592RA (en) 2018-07-30

Family

ID=57960827

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805592RA SG11201805592RA (en) 2016-01-15 2017-01-13 Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor

Country Status (10)

Country Link
US (1) US10712344B2 (en)
EP (2) EP3889176A1 (en)
JP (3) JP6902548B2 (en)
KR (1) KR102512608B1 (en)
CN (1) CN109952313B (en)
AU (2) AU2017207450B2 (en)
CA (1) CA3011087A1 (en)
SG (1) SG11201805592RA (en)
TW (2) TWI821913B (en)
WO (1) WO2017123978A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
IL287311B1 (en) 2008-05-16 2024-02-01 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
EP2966084B1 (en) 2008-08-28 2018-04-25 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
CN114645015A (en) 2012-07-20 2022-06-21 泰加生物工艺学公司 Enhanced reconstitution and autoreconstitution of hematopoietic compartments
EP3318295B1 (en) 2012-10-11 2021-04-14 Magnolia Medical Technologies, Inc. System for delivering a fluid to a patient with reduced contamination
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
TWI808934B (en) 2015-12-31 2023-07-21 美商伯克利之光生命科技公司 Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide
EP3429753A4 (en) 2016-03-16 2019-11-06 Berkeley Lights, Inc. Methods, systems and devices for selection and generation of genome edited clones
US10583156B2 (en) 2016-12-02 2020-03-10 Taiga Biotechnologies, Inc. Nanoparticle formulations
CA3046827A1 (en) 2016-12-12 2018-06-21 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
AU2017388874A1 (en) 2016-12-30 2019-07-18 Berkeley Lights, Inc. Methods for selection and generation of genome edited T cells
JP6992079B2 (en) 2017-04-23 2022-01-13 ヒューレット－パッカード デベロップメント カンパニー エル．ピー． Particle separation
EP3635112A2 (en) 2017-06-06 2020-04-15 Zymergen, Inc. A htp genomic engineering platform for improving fungal strains
ES2905757T3 (en) * 2017-08-03 2022-04-12 Taiga Biotechnologies Inc Methods and compositions for the treatment of melanoma
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN116250868A (en) 2017-09-12 2023-06-13 木兰医药技术股份有限公司 Fluid control device and method of using the same
US10871440B2 (en) 2017-12-23 2020-12-22 Lumacyte, LLC Microfluidic chip device for optical force measurements and cell imaging using microfluidic chip configuration and dynamics
SG11202011180UA (en) * 2018-05-31 2020-12-30 Berkeley Lights Inc Automated detection and characterization of micro-objects in microfluidic devices
KR20210018219A (en) 2018-06-06 2021-02-17 지머젠 인코포레이티드 Modification of genes involved in signaling to control fungal morphology during fermentation and production
CN113784793B (en) 2019-03-11 2023-09-19 木兰医药技术股份有限公司 Fluid control device and method of using the same
CN111808815A (en) * 2019-04-11 2020-10-23 北京基石生命科技有限公司 Method for culturing primary cells of gastric cancer solid tumor
WO2020233503A1 (en) * 2019-05-17 2020-11-26 University Of Macau Detection method
CN114007867B (en) 2019-06-25 2024-04-16 惠普发展公司，有限责任合伙企业 Molded structure with channels
US11335636B2 (en) * 2019-10-29 2022-05-17 Hefei Reliance Memory Limited Gradual breakdown memory cell having multiple different dielectrics
CA3158045A1 (en) * 2019-11-21 2021-05-27 Emulate Inc. Antibody producing microfluidic devices
JPWO2022004620A1 (en) * 2020-06-29 2022-01-06
JP7197538B2 (en) * 2020-07-03 2022-12-27 タイガ バイオテクノロジーズ，インク． Methods and compositions for treating melanoma
US11479779B2 (en) 2020-07-31 2022-10-25 Zymergen Inc. Systems and methods for high-throughput automated strain generation for non-sporulating fungi
US20220304664A1 (en) * 2021-03-26 2022-09-29 Jeremy Hammer Apparatus and methods for bodily fluid sample collection
US11763647B2 (en) * 2021-08-16 2023-09-19 City University Of Hong Kong Multimode haptic patch and multimodal haptic feedback interface
CN113996355B (en) * 2021-10-28 2023-06-06 上海浚真生命科学有限公司 Sampling device
WO2023133895A1 (en) * 2022-01-17 2023-07-20 深圳华大生命科学研究院 Method for obtaining information on nanoantibody specifically recognizing antigen
CN114574587B (en) * 2022-04-06 2022-12-02 北京莱盟君泰国际医疗技术开发有限公司 Marker composition for colorectal cancer detection and application thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2618497B2 (en) * 1989-10-03 1997-06-11 鐘淵化学工業株式会社 Tumor-damaging cell inducer and tumor-damaging cell induction device
CA2255599C (en) 1996-04-25 2006-09-05 Bioarray Solutions, Llc Light-controlled electrokinetic assembly of particles near surfaces
US6294063B1 (en) 1999-02-12 2001-09-25 Board Of Regents, The University Of Texas System Method and apparatus for programmable fluidic processing
US6942776B2 (en) 1999-05-18 2005-09-13 Silicon Biosystems S.R.L. Method and apparatus for the manipulation of particles by means of dielectrophoresis
EP1328803B1 (en) * 2000-06-14 2005-09-07 The Board Of Regents, The University Of Texas System Systems and methods for cell subpopulation analysis
US20030007894A1 (en) 2001-04-27 2003-01-09 Genoptix Methods and apparatus for use of optical forces for identification, characterization and/or sorting of particles
ITTO20010411A1 (en) 2001-05-02 2002-11-02 Silicon Biosystems S R L METHOD AND DEVICE FOR THE EXECUTION OF TESTS AND TESTS WITH HIGH PROCESSIVITY AND HIGH BIOLOGICAL VALUE ON CELLS AND / OR COMPOUNDS.
US7312085B2 (en) 2002-04-01 2007-12-25 Fluidigm Corporation Microfluidic particle-analysis systems
US6958132B2 (en) 2002-05-31 2005-10-25 The Regents Of The University Of California Systems and methods for optical actuation of microfluidics based on opto-electrowetting
EP1561107A1 (en) * 2002-11-13 2005-08-10 Micromet AG Method for identifying antigen specific b cells
JP4328168B2 (en) 2003-10-02 2009-09-09 ソニー株式会社 Detection unit for interaction between substances using capillary phenomenon, method using the detection unit, and substrate for bioassay
US7425253B2 (en) 2004-01-29 2008-09-16 Massachusetts Institute Of Technology Microscale sorting cytometer
EP1735428A4 (en) 2004-04-12 2010-11-10 Univ California Optoelectronic tweezers for microparticle and cell manipulation
US20060091015A1 (en) 2004-11-01 2006-05-04 Applera Corporation Surface modification for non-specific adsorption of biological material
EP1915467A2 (en) 2005-08-19 2008-04-30 The Regents of the University of California Microfluidic methods for diagnostics and cellular analysis
EP1951742A4 (en) 2005-10-27 2011-06-01 Life Technologies Corp Optoelectronic separation of biomolecules
WO2007092713A2 (en) * 2006-02-02 2007-08-16 Trustees Of The University Of Pennsylvania Microfluidic system and method for analysis of gene expression in cell-containing samples and detection of disease
CN105056231A (en) * 2006-12-28 2015-11-18 詹森生物科技公司 Methods and vectors for generating asialylated immunoglobulins
US8685344B2 (en) 2007-01-22 2014-04-01 Advanced Liquid Logic, Inc. Surface assisted fluid loading and droplet dispensing
WO2008119066A1 (en) 2007-03-28 2008-10-02 The Regents Of The University Of California Single-sided lateral-field and phototransistor-based optoelectronic tweezers
ATE554859T1 (en) 2007-05-24 2012-05-15 Univ California INTEGRATED FLUIDIC DEVICES WITH MAGNETIC SORTING
US20090068170A1 (en) 2007-07-13 2009-03-12 President And Fellows Of Harvard College Droplet-based selection
US20100086919A1 (en) * 2008-04-11 2010-04-08 China Molecular, Ltd. Devices and methods for immunoglobulin production
US20110117634A1 (en) 2008-04-21 2011-05-19 Asaf Halamish Flat cell carriers with cell traps
WO2010053987A2 (en) * 2008-11-04 2010-05-14 Duke University Monoclonal antibody production in b cells and uses therof
US20120045827A1 (en) * 2009-03-09 2012-02-23 Biofactura, Inc. Separation of antigen-specific memory b cells with a conjugated biopolymer surface
EP2414539B1 (en) 2009-04-03 2020-12-16 The Regents of The University of California Apparatus and method for sorting cells and other biological particulates
GB0909923D0 (en) 2009-06-09 2009-07-22 Oxford Gene Tech Ip Ltd Picowell capture devices for analysing single cells or other particles
US20130118905A1 (en) 2010-05-26 2013-05-16 Tosoh Corporation Biological sample immobilizing apparatus
CN101947124B (en) 2010-06-25 2012-07-04 博奥生物有限公司 Integrated microfluidic chip device and using method thereof
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
US9533306B2 (en) 2010-08-02 2017-01-03 The Regents Of The University Of California Single sided continuous optoelectrowetting (SCEOW) device for droplet manipulation with light patterns
WO2012037030A2 (en) 2010-09-14 2012-03-22 The Regents Of The University Of California Method and device for isolating cells from heterogeneous solution using microfluidic trapping vortices
WO2012072823A1 (en) 2010-12-03 2012-06-07 Mindseeds Laboratories Srl Rapid screening of monoclonal antibodies
US20140154703A1 (en) 2011-01-06 2014-06-05 Alison Skelley Circulating tumor cell capture on a microfluidic chip incorporating both affinity and size
KR102117921B1 (en) * 2011-02-28 2020-06-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Cell culture system
US9227200B2 (en) 2011-06-03 2016-01-05 The Regents Of The University Of California Microfluidic devices with flexible optically transparent electrodes
US9103754B2 (en) 2011-08-01 2015-08-11 Denovo Sciences, Inc. Cell capture system and method of use
EP2805166B1 (en) * 2012-01-20 2018-11-21 INSERM - Institut National de la Santé et de la Recherche Médicale Method for the prognosis of survival time of a patient suffering from a solid cancer
JP6317353B2 (en) * 2012-09-13 2018-04-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Method for multiple analytical measurements in single cells of solid tissue
US9857333B2 (en) * 2012-10-31 2018-01-02 Berkeley Lights, Inc. Pens for biological micro-objects
US9403172B2 (en) 2012-11-08 2016-08-02 Berkeley Lights, Inc. Circuit based optoelectronic tweezers
KR102402451B1 (en) 2013-03-28 2022-05-26 더 유니버시티 오브 브리티쉬 콜롬비아 Microfluidic devices and methods for use thereof in multicellular assays of secretion
IL283153B2 (en) * 2013-10-22 2023-04-01 Berkeley Lights Inc Microfluidic devices having isolation pens and methods of testing biological micro-objects with same
US9889445B2 (en) * 2013-10-22 2018-02-13 Berkeley Lights, Inc. Micro-fluidic devices for assaying biological activity
SG10202002543UA (en) 2013-10-22 2020-05-28 Berkeley Lights Inc Micro-fluidic devices for assaying biological activity
US20150306599A1 (en) 2014-04-25 2015-10-29 Berkeley Lights, Inc. Providing DEP Manipulation Devices And Controllable Electrowetting Devices In The Same Microfluidic Apparatus
US20150306598A1 (en) 2014-04-25 2015-10-29 Berkeley Lights, Inc. DEP Force Control And Electrowetting Control In Different Sections Of The Same Microfluidic Apparatus
CN106461696B (en) 2014-04-25 2019-06-07 伯克利之光生命科技公司 DEP controlling equipment and controllable electrowetting device are provided in same microfluidic device
US20150352547A1 (en) 2014-06-06 2015-12-10 Berkeley Lights, Inc. Isolating Microfluidic Structures and Trapping Bubbles
CN104293666B (en) * 2014-09-11 2016-06-22 大连理工大学 The micro flow control chip device of the interphase interaction that two kinds of differences are unicellular
TWI721545B (en) 2014-12-08 2021-03-11 美商柏克萊燈光有限公司 Lateral/vertical transistor structures and processes of making and using same
TWI700125B (en) 2014-12-10 2020-08-01 美商柏克萊燈光有限公司 Systems for operating electrokinetic devices
KR102538721B1 (en) 2015-04-22 2023-05-31 버클리 라잇츠, 인크. Microfluidic cell culture

Also Published As

Publication number Publication date
EP3402814B1 (en) 2021-04-21
TW202221321A (en) 2022-06-01
CN109952313B (en) 2023-12-19
TW201734207A (en) 2017-10-01
CN109952313A (en) 2019-06-28
AU2022200495A1 (en) 2022-02-17
JP2021153594A (en) 2021-10-07
US20200400669A1 (en) 2020-12-24
AU2017207450A1 (en) 2018-07-19
US10712344B2 (en) 2020-07-14
JP2019511454A (en) 2019-04-25
JP6902548B2 (en) 2021-07-14
TWI756199B (en) 2022-03-01
AU2017207450B2 (en) 2021-11-04
CA3011087A1 (en) 2017-07-20
EP3402814A1 (en) 2018-11-21
TWI821913B (en) 2023-11-11
EP3889176A1 (en) 2021-10-06
KR102512608B1 (en) 2023-03-22
JP2023082046A (en) 2023-06-13
KR20180101548A (en) 2018-09-12
US20170276679A1 (en) 2017-09-28
WO2017123978A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
SG11201805592RA (en) Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201908787WA (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201808022WA (en) Selection and cloning of t lymphocytes in a microfluidic device
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201808125RA (en) Methods for solid tumor treatment
SG11201808573YA (en) Nucleic acid stabilization reagent, kits, and methods of use thereof
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201805496PA (en) An immunoassay for the diagnosis of viral infections
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201908127WA (en) Method for producing multispecific antibodies
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201804714XA (en) Electrode integration into organs on chip devices
SG11201903202VA (en) Osmotic membrane
SG11201909048TA (en) Use of klk5 antagonists for treatment of a disease